Loading...

Buy Full Version
"Beta-lactam and Beta-lactamase Inhibitors Market"

Let us help you !

Invalid Email.

Please Select Country.

Invalid contact no.

Special Symbols Not Allowed.

Invalid Security Code.

Thank You For Your Interest.

We've Successfully Got Your Message,

Our Executive will get back to you Shortly.

Beta-lactam and Beta-lactamase Inhibitors Market by Drug Class (Penicillin, Cephalosporin, Carbapenem, Monobactam, and Combination), Disease (Urinary Tract Infection, Respiratory Infection, Skin Infection, Complicated Urinary Tract Infection (cUTI), Complicated Intra-Abdominal Infections (cIAI), Nosocomial Pneumonia, Blood Stream Infection, and Other Diseases), and Route of Administration (Oral, Intravenous, and Other Route of Administrations): Global Opportunity Analysis and Industry Forecast, 2019–2028

LI_195427
Pages: 309
Aug 2019 | 535 Views
 
Author(s) : Surabhi Pandey , Onkar Sumant
Tables: 139
Charts: 60
 

Beta-lactam and Beta-lactamase Inhibitors Market Outlook - 2028

The global beta-lactam and beta-lactamase inhibitors market size was $27,126 million in 2018, and is projected to reach $34,170 million by 2028, growing at a CAGR of 2.3% from 2019 to 2028.

Beta-lactam antibiotics are a class of antibiotics consisting of all antibiotic agents that contain a beta-lactam ring in their molecular structures. This includes penicillin derivatives, cephalosporins, monobactams, and carbapenems. These are the antimicrobial substances or compounds that fight against bacterial infections and sometimes with protozoan infections. In addition, these medications either kill the bacteria directly or stop the bacteria from growing. However, these drugs are easily available at over-the-counter (OTC) and one can buy these without a prescription in most of the countries, which leads to overuse or misuse. Thereby, bacterial resistance is developing the beta-lactam antibiotics. Beta-lactamase enzymes are produced either constitutively or on exposure to antimicrobials. These enzymes break the beta-lactam ring of vulnerable penicillin & cephalosporin and inactivating the antibiotic to work against bacteria. Hence, beta-lactamase inhibitors are used in combination with the beta-lactam. Beta-lactamase inhibitors are a class of medicine that block the activity of beta-lactamase enzymes and prevent the degradation of beta-lactam antibiotics. Furthermore, there are many new drugs in the pipeline, which are expected to be launched during the forecast period and will create an opportunity for the global beta-lactam and beta-lactamase inhibitors market players.

Beta-lactam and Beta-lactamase Inhibitors Market

Get more information on this report : Request Sample Pages

The growth of the global beta-lactam and beta-lactamase inhibitors market is driven by increased consumption in low- and middle-income countries (LMICs) and rise in prevalence of infectious diseases. In addition, development of novel approaches for new beta-lactam and beta-lactamase inhibitors for treating bacterial infections and a large number of clinical trials further drive the market growth. However, development of antibiotic resistance, driven by misuse of beta-lactam and beta-lactamase inhibitors and the time taken for the regulatory approval is projected to impede the market growth. On the contrary, discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer significant profitable opportunities for the market players and hence increases the beta-lactam and beta-lactamase inhibitors market share.

Beta-lactam and Beta-lactamase Inhibitors Market by Drug Class

Get more information on this report : Request Sample Pages

 

Drug class segment review

Based on the drug class, the market is classified into penicillin, cephalosporin, carbapenem, monobactam, and combination. Combination segment is further categorized into penicillin/beta lactamase inhibitors, cephalosporins/beta lactamase inhibitors, and carbapenems/beta lactamase inhibitors. The cephalosporin segment was the major revenue contributor in 2018, and is anticipated to continue this trend during the beta-lactam and beta-lactamase inhibitors market forecast period. This is attributed to its broad-spectrum activity and development of the next-generation cephalosporin, which can fight against antimicrobial resistance. In addition, it heals infections caused due to multiple groups of bacteria. Thus, the demand for cephalosporin is high among the healthcare providers and patients, which in turn fuels the growth of the global market.

Beta-lactam and Beta-lactamase Inhibitors Market by Disease

Get more information on this report : Request Sample Pages

Disease segment review

Depending upon the disease segment, the market is divided into urinary tract infection (excluding cUTI), respiratory infection, skin infection, complicated urinary tract infection (cUTI), complicated intra-abdominal infections (cIAI), nosocomial pneumonia, blood stream infection, and other diseases. The nosocomial pneumonia segment is further divided into hospital acquired pneumonia, ventilator associated pneumonia, and other nosocomial pneumonia. The cIAI segment is projected to exhibit the highest growth during the forecast period. This is attributed to the increase in burden of sepsis and rapid rise in mortality rate with greater disease severity across the world; and cIAI is one the most common cause of severe sepsis. In addition, complicated IAI extends beyond the source organ into the peritoneal space which causes peritoneal inflammation. Moreover, the mortality rate in severe IAIs are significantly high, which in turn increases the demand for novel drugs and boosts the growth of the beta-lactam and beta-lactamase inhibitors market.

Beta-lactam and Beta-lactamase Inhibitors Market by Region

Get more information on this report : Request Sample Pages

Region segment review

Region wise, the beta-lactam and beta-lactamase inhibitors market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. LAMEA is projected to exhibit the highest growth during the forecast period, owing to the easy obtainability of beta-lactam and beta-lactamase inhibitors over-the-counter as well as there are no legislation or restrictions on their use in this region. However, Asia-Pacific was the leading revenue contributor to the global beta-lactam and beta-lactamase inhibitors market in 2018, and is expected to remain dominant throughout the forecast period, due to increase in consumption of beta-lactam and beta-lactamase inhibitors, easy availability of these drugs, and rise in sale of beta-lactam and beta-lactamase inhibitors without prescription.

The report provides a comprehensive beta-lactam and beta-lactamase inhibitors market analysis of the key players operating in the global beta-lactam and beta-lactamase inhibitors market, namely, Abbott Laboratories, Allergan Plc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co. Inc., Mylan N.V., Novartis International AG (Sandoz), Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd. The other players in the value chain include Hikma Pharmaceuticals, Melinta Therapeutics, Eli Lilly and Company, Shionogi, Inc., AstraZeneca plc, and others.

Key Benefits for Beta-lactam and Beta-lactamase Inhibitors Market:

  • This report provides a detailed quantitative analysis of the current beta-lactam and beta-lactamase inhibitors market trends and estimations from 2018 to 2028, which assists to identify the prevailing opportunities. 
  • An in-depth market analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
  • A comprehensive analysis of the factors that drive and restrain the beta-lactam and beta-lactamase inhibitors market growth of the market is provided.
  • Region-wise and country-wise market conditions are comprehensively analyzed in this report.
  • The projections in this report are made by analyzing the current trends and future market potential from 2019 to 2028 in terms of value.
  • An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.
  • Key market players within the market are profiled in this report and their strategies are analyzed thoroughly, which helps to understand the competitive outlook of the global market.

Beta-lactam and Beta-lactamase Inhibitors Market Segments:

By Drug Class

  • Penicillin
  • Cephalosporin
  • Carbapenem
  • Monobactam
  • Combination
    • Penicillin/Beta Lactamase Inhibitors
    • Cephalosporins/Beta Lactamase Inhibitors
    • Carbapenems/Beta Lactamase Inhibitors

By Disease

  • Urinary Tract Infection (excluding cUTI)
  • Respiratory Infection
  • Skin Infection
  • Complicated Urinary Tract Infection (cUTI)
  • Complicated Intra-Abdominal Infections (cIAI)
  • Nosocomial Pneumonia
    • Hospital Acquired Pneumonia
    • Ventilator Associated Pneumonia
    • Other Nosocomial Pneumonia
  • Blood Stream Infection
  • Other Diseases

By Route of Administration

  • Oral
  • Intravenous
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • Spain
    • Italy
    • UK
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • India
    • China
    • South Korea
    • Thailand
    • Taiwan
    • Vietnam
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:    INTRODUCTION

1.1.    Report description
1.2.    Key benefits for stakeholders
1.3.    Key market segments

1.3.1.    List of key players profiled in the report

1.4.    Research methodology

1.4.1.    Secondary research
1.4.2.    Primary research
1.4.3.    Analyst tools and models

CHAPTER 2:    EXECUTIVE SUMMARY

2.1.1.    CXO perspective

CHAPTER 3:    MARKET OVERVIEW

3.1.    Market definition and scope
3.2.    Key findings

3.2.1.    Top investment pockets

3.3.    Top winning strategies

3.3.1.    Top Player Positioning, 2018

3.4.    Porter’s five forces analysis
3.5.    Market dynamics

3.5.1.    Drivers

3.5.1.1.    Increased consumption in low and middle-income countries (LMICs)
3.5.1.2.    Rise in prevalence of infectious diseases
3.5.1.3.    Development of novel approaches for new beta-lactam and beta-lactamase inhibitors for treating bacterial infections

3.5.2.    Restraints

3.5.2.1.    Development of beta-lactam resistance
3.5.2.2.    Longer approval time by the regulatory bodies

3.5.3.    Opportunity

3.5.3.1.    Discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections

3.6.    Antimicrobial resistance and countermeasure trends

3.6.1.    Countermeasure trends

CHAPTER 4:    BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET,  BY DRUG CLASS

4.1.    Overview

4.1.1.    Market size and forecast

4.2.    Penicillin

4.2.1.    Key market trends and growth opportunities
4.2.2.    Market size and forecast, by region
4.2.3.    Market analysis, by country

4.3.    Cephalosporin

4.3.1.    Key market trends and growth opportunities
4.3.2.    Market size and forecast, by region
4.3.3.    Market analysis, by country

4.4.    Carbapenem

4.4.1.    Key market trends and growth opportunities
4.4.2.    Market size and forecast, by region
4.4.3.    Market analysis, by country

4.5.    Monobactam

4.5.1.    Key market trends and growth opportunities
4.5.2.    Market size and forecast, by region
4.5.3.    Market analysis, by country

4.6.    Combination

4.6.1.    Key market trends and growth opportunities
4.6.2.    Market size and forecast, by type

4.6.2.1.    Penicillin/Beta Lactamase Inhibitors

4.6.2.1.1.    Market size and forecast

4.6.2.2.    Cephalosporins/Beta Lactamase Inhibitors

4.6.2.2.1.    Market size and forecast

4.6.2.3.    Carbapenems/Beta Lactamase Inhibitors

4.6.2.3.1.    Market size and forecast

4.6.3.    Market size and forecast, by region
4.6.4.    Market analysis, by country

CHAPTER 5:    BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET, BY DISEASE

5.1.    Overview

5.1.1.    Market size and forecast

5.2.    Urinary Tract Infection (Excluding cUTI)

5.2.1.    Market size and forecast, by region
5.2.2.    Market analysis, by country

5.3.    Respiratory Infection

5.3.1.    Market size and forecast, by region
5.3.2.    Market analysis, by country

5.4.    Skin Infection

5.4.1.    Market size and forecast, by region
5.4.2.    Market analysis, by country

5.5.    Complicated Urinary Tract Infection (cUTI)

5.5.1.    Market size and forecast, by region
5.5.2.    Market analysis, by country
5.5.3.    Number of Patients, by country

5.6.    Complicated Intra-Abdominal Infections (cIAI)

5.6.1.    Market size and forecast, by region
5.6.2.    Market analysis, by country
5.6.3.    Number of Patients, by country

5.7.    Nosocomial Pneumonia

5.7.1.    Market size and forecast, by type

5.7.1.1.    Hospital Acquired Pneumonia

5.7.1.1.1.    Market size and forecast

5.7.1.2.    Ventilator Associated Pneumonia

5.7.1.2.1.    Market size and forecast

5.7.1.3.    Other Nosocomial Pneumonia

5.7.1.3.1.    Market size and forecast

5.7.2.    Market size and forecast, by region
5.7.3.    Market analysis, by country
5.7.4.    Number of Patients, by country

5.8.    Blood Stream Infection

5.8.1.    Market size and forecast, by region
5.8.2.    Market analysis, by country
5.8.3.    Number of Patients, by country

5.9.    Other Diseases

5.9.1.    Market size and forecast, by region
5.9.2.    Market analysis, by country

CHAPTER 6:    BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

6.1.    Overview

6.1.1.    Market size and forecast

6.2.    Oral

6.2.1.    Market size and forecast, by region
6.2.2.    Market analysis, by country

6.3.    Intravenous

6.3.1.    Market size and forecast, by region
6.3.2.    Market analysis, by country

6.4.    Others

6.4.1.    Market size and forecast, by region
6.4.2.    Market analysis, by country

CHAPTER 7:    BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY REGION

7.1.    Overview

7.1.1.    Market size and forecast

7.2.    North America

7.2.1.    Key market trends and opportunities
7.2.2.    North America beta-lactam and beta-lactamase inhibitors market, by country

7.2.2.1.    U.S. beta-lactam and beta-lactamase inhibitors market by drug class
7.2.2.2.    U.S. beta-lactam and beta-lactamase inhibitors market by disease
7.2.2.3.    U.S. beta-lactam and beta-lactamase inhibitors market by route of administration
7.2.2.4.    Canada beta-lactam and beta-lactamase inhibitors market by drug class
7.2.2.5.    Canada beta-lactam and beta-lactamase inhibitors market by disease
7.2.2.6.    Canada beta-lactam and beta-lactamase inhibitors market by route of administration
7.2.2.7.    Mexico beta-lactam and beta-lactamase inhibitors market by drug class
7.2.2.8.    Mexico beta-lactam and beta-lactamase inhibitors market by disease
7.2.2.9.    Mexico beta-lactam and beta-lactamase inhibitors market by route of administration

7.2.3.    North America beta-lactam and beta-lactamase inhibitors market, by drug class
7.2.4.    North America beta-lactam and beta-lactamase inhibitors market, by disease
7.2.5.    North America beta-lactam and beta-lactamase inhibitors market, by route of administration

7.3.    Europe

7.3.1.    Key market trends and opportunities
7.3.2.    Europe beta-lactam and beta-lactamase inhibitors market, by country

7.3.2.1.    Germany beta-lactam and beta-lactamase inhibitors market by drug class
7.3.2.2.    Germany beta-lactam and beta-lactamase inhibitors market by disease
7.3.2.3.    Germany beta-lactam and beta-lactamase inhibitors market by route of administration
7.3.2.4.    France beta-lactam and beta-lactamase inhibitors market by drug class
7.3.2.5.    France beta-lactam and beta-lactamase inhibitors market by disease
7.3.2.6.    France beta-lactam and beta-lactamase inhibitors market by route of administration
7.3.2.7.    Spain beta-lactam and beta-lactamase inhibitors market by drug class
7.3.2.8.    Spain beta-lactam and beta-lactamase inhibitors market by disease
7.3.2.9.    Spain beta-lactam and beta-lactamase inhibitors market by route of administration
7.3.2.10.    Italy beta-lactam and beta-lactamase inhibitors market by drug class
7.3.2.11.    Italy beta-lactam and beta-lactamase inhibitors market by disease
7.3.2.12.    Italy beta-lactam and beta-lactamase inhibitors market by route of administration
7.3.2.13.    UK beta-lactam and beta-lactamase inhibitors market by drug class
7.3.2.14.    UK beta-lactam and beta-lactamase inhibitors market by disease
7.3.2.15.    UK beta-lactam and beta-lactamase inhibitors market by route of administration
7.3.2.16.    Rest of Europe beta-lactam and beta-lactamase inhibitors market by drug class
7.3.2.17.    Rest of Europe beta-lactam and beta-lactamase inhibitors market by disease
7.3.2.18.    Rest of Europe beta-lactam and beta-lactamase inhibitors market by route of administration

7.3.3.    Europe beta-lactam and beta-lactamase inhibitors market, by drug class
7.3.4.    Europe beta-lactam and beta-lactamase inhibitors market, by disease
7.3.5.    Europe beta-lactam and beta-lactamase inhibitors market, by route of administration

7.4.    Asia-Pacific

7.4.1.    Key market trends and opportunities
7.4.2.    Asia-Pacific beta-lactam and beta-lactamase inhibitors market, by country

7.4.2.1.    Japan beta-lactam and beta-lactamase inhibitors market by drug class
7.4.2.2.    Japan beta-lactam and beta-lactamase inhibitors market by disease
7.4.2.3.    Japan beta-lactam and beta-lactamase inhibitors market by route of administration
7.4.2.4.    India beta-lactam and beta-lactamase inhibitors market by drug class
7.4.2.5.    India beta-lactam and beta-lactamase inhibitors market by disease
7.4.2.6.    India beta-lactam and beta-lactamase inhibitors market by route of administration
7.4.2.7.    China beta-lactam and beta-lactamase inhibitors market by drug class
7.4.2.8.    China beta-lactam and beta-lactamase inhibitors market by disease
7.4.2.9.    China beta-lactam and beta-lactamase inhibitors market by route of administration
7.4.2.10.    South Korea beta-lactam and beta-lactamase inhibitors market by drug class
7.4.2.11.    South Korea beta-lactam and beta-lactamase inhibitors market by disease
7.4.2.12.    South Korea beta-lactam and beta-lactamase inhibitors market by Route of administration
7.4.2.13.    Indonesia beta-lactam and beta-lactamase inhibitors market by drug class
7.4.2.14.    Indonesia beta-lactam and beta-lactamase inhibitors market by disease
7.4.2.15.    Indonesia beta-lactam and beta-lactamase inhibitors market by Route of administration
7.4.2.16.    Thailand beta-lactam and beta-lactamase inhibitors market by drug class
7.4.2.17.    Thailand beta-lactam and beta-lactamase inhibitors market by disease
7.4.2.18.    Thailand beta-lactam and beta-lactamase inhibitors market by Route of administration
7.4.2.19.    Vietnam beta-lactam and beta-lactamase inhibitors market by drug class
7.4.2.20.    Vietnam beta-lactam and beta-lactamase inhibitors market by disease
7.4.2.21.    Vietnam beta-lactam and beta-lactamase inhibitors market by Route of administration
7.4.2.22.    Taiwan beta-lactam and beta-lactamase inhibitors market by drug class
7.4.2.23.    Taiwan beta-lactam and beta-lactamase inhibitors market by disease
7.4.2.24.    Taiwan beta-lactam and beta-lactamase inhibitors market by Route of administration
7.4.2.25.    Rest of Asia-Pacific beta-lactam and beta-lactamase inhibitors market by drug class
7.4.2.26.    Rest of Asia-Pacific beta-lactam and beta-lactamase inhibitors market by disease
7.4.2.27.    Rest of Asia-Pacific beta-lactam and beta-lactamase inhibitors market by route of administration

7.4.3.    Asia-Pacific beta-lactam and beta-lactamase inhibitors market, by drug class
7.4.4.    Asia-Pacific beta-lactam and beta-lactamase inhibitors market, by disease
7.4.5.    Asia-Pacific beta-lactam and beta-lactamase inhibitors market, by route of administration

7.5.    LAMEA

7.5.1.    Key market trends and opportunities
7.5.2.    LAMEA beta-lactam and beta-lactamase inhibitors market, by country

7.5.2.1.    Brazil beta-lactam and beta-lactamase inhibitors market by drug class
7.5.2.2.    Brazil beta-lactam and beta-lactamase inhibitors market by disease
7.5.2.3.    Brazil beta-lactam and beta-lactamase inhibitors market by Route of administration
7.5.2.4.    Saudi Arabia beta-lactam and beta-lactamase inhibitors market by drug class
7.5.2.5.    Saudi Arabia beta-lactam and beta-lactamase inhibitors market by disease
7.5.2.6.    Saudi Arabia beta-lactam and beta-lactamase inhibitors market by route of administration
7.5.2.7.    South Africa beta-lactam and beta-lactamase inhibitors market by drug class
7.5.2.8.    South Africa beta-lactam and beta-lactamase inhibitors market by disease
7.5.2.9.    South Africa beta-lactam and beta-lactamase inhibitors market by route of administration
7.5.2.10.    Rest of LAMEA beta-lactam and beta-lactamase inhibitors market by drug class
7.5.2.11.    Rest of LAMEA beta-lactam and beta-lactamase inhibitors market by disease
7.5.2.12.    Rest of LAMEA beta-lactam and beta-lactamase inhibitors market by route of administration

7.5.3.    LAMEA beta-lactam and beta-lactamase inhibitors market, by drug class
7.5.4.    LAMEA beta-lactam and beta-lactamase inhibitors market, by disease
7.5.5.    LAMEA beta-lactam and beta-lactamase inhibitors market, by route of administration

CHAPTER 8:    COMPANY PROFILES

8.1.    Abbott Laboratories

8.1.1.    Company overview
8.1.2.    Company snapshot
8.1.3.    Operating business segments
8.1.4.    Product portfolio
8.1.5.    Business performance

8.2.    Allergan Plc.

8.2.1.    Company overview
8.2.2.    Company snapshot
8.2.3.    Operating business segments
8.2.4.    Product portfolio
8.2.5.    Business performance
8.2.6.    Key strategic moves and developments

8.3.    F. Hoffmann-La Roche Ltd.

8.3.1.    Company overview
8.3.2.    Company snapshot
8.3.3.    Operating business segments
8.3.4.    Product portfolio
8.3.5.    Business performance

8.4.    GlaxoSmithKline plc

8.4.1.    Company overview
8.4.2.    Company snapshot
8.4.3.    Operating business segments
8.4.4.    Product portfolio
8.4.5.    Business performance

8.5.    Merck & Co. Inc.

8.5.1.    Company overview
8.5.2.    Company snapshot
8.5.3.    Operating business segments
8.5.4.    Product portfolio
8.5.5.    Business performance
8.5.6.    Key strategic moves and developments

8.6.    Mylan N.V.

8.6.1.    Company overview
8.6.2.    Company snapshot
8.6.3.    Operating business segments
8.6.4.    Product portfolio
8.6.5.    Business performance
8.6.6.    Key strategic moves and developments

8.7.    Novartis International AG (Sandoz)

8.7.1.    Company overview
8.7.2.    Company snapshot
8.7.3.    Operating business segments
8.7.4.    Product portfolio
8.7.5.    Business performance

8.8.    Pfizer Inc.

8.8.1.    Company overview
8.8.2.    Company snapshot
8.8.3.    Operating business segments
8.8.4.    Product portfolio
8.8.5.    Business performance
8.8.6.    Key strategic moves and developments

8.9.    Sanofi

8.9.1.    Company overview
8.9.2.    Company snapshot
8.9.3.    Operating business segments
8.9.4.    Product portfolio
8.9.5.    Business performance

8.10.    Teva Pharmaceutical Industries Ltd.

8.10.1.    Company overview
8.10.2.    Company snapshot
8.10.3.    Operating business segments
8.10.4.    Product portfolio
8.10.5.    Business performance

LIST OF TABLES

TABLE 01.    CLASSIFICATION OF BETA-LACTAMASE INHIBITORS AND ITS PROPERTIES
TABLE 02.    GLOBAL BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET, BY DRUG CLASS, 2018–2028 ($MILLION)
TABLE 03.    BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR PENICILLIN, BY REGION, 2018–2028 ($MILLION)
TABLE 04.    BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR CEPHALOSPORIN, BY REGION, 2018–2028 ($MILLION)
TABLE 05.    BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR CARBAPENEM, BY REGION, 2018–2028 ($MILLION)
TABLE 06.    BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR MONOBACTAM, BY REGION, 2018–2028 ($MILLION)
TABLE 07.    BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR COMBINATION, BY TYPE, 2018–2028 ($MILLION)
TABLE 08.    BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR COMBINATION, BY REGION, 2018–2028 ($MILLION)
TABLE 09.    GLOBAL BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET, BY DISEASE, 2018–2028 ($MILLION)
TABLE 10.    BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR URINARY TRACT INFECTION (EXCLUDING CUTI), BY REGION, 2018–2028 ($MILLION)
TABLE 11.    BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR RESPIRATORY INFECTION, BY REGION, 2018–2028 ($MILLION)
TABLE 12.    BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR SKIN INFECTION, BY REGION, 2018–2028 ($MILLION)
TABLE 13.    BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR COMPLICATED URINARY TRACT INFECTION (CUTI), BY REGION, 2018–2028 ($MILLION)
TABLE 14.    NUMBER OF PATIENTS FOR COMPLICATED URINARY TRACT INFECTION (CUTI), BY COUNTRY, 2018–2028 (THOUSANDS)
TABLE 15.    BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), BY REGION, 2018–2028 ($MILLION)
TABLE 16.    NUMBER OF PATIENTS FOR COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), BY COUNTRY, 2018–2028 (THOUSANDS)
TABLE 17.    BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET FOR NOSOCOMIAL PNEUMONIA, BY TYPE, 2018–2028 ($MILLION)
TABLE 18.    BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR NOSOCOMIAL PNEUMONIA, BY REGION, 2018–2028 ($MILLION)
TABLE 19.    NUMBER OF PATIENTS FOR NOSOCOMIAL PNEUMONIA, BY COUNTRY, 2018–2028 (THOUSANDS)
TABLE 20.    BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR BLOOD STREAM INFECTION, BY REGION, 2018–2028 ($MILLION)
TABLE 21.    NUMBER OF PATIENTS FOR BLOOD STREAM INFECTION, BY COUNTRY, 2018–2028 (THOUSANDS)
TABLE 22.    BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR OTHER DISEASES, BY REGION, 2018–2028 ($MILLION)
TABLE 23.    GLOBAL BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2028 ($MILLION)
TABLE 24.    BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR ORAL, BY REGION, 2018–2028 ($MILLION)
TABLE 25.    BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR INTRAVENOUS, BY REGION, 2018–2028 ($MILLION)
TABLE 26.    BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR OTHERS, BY REGION, 2018–2028 ($MILLION)
TABLE 27.    GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET REVENUE, BY REGION, 2018–2028 ($MILLION)
TABLE 28.    NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY COUNTRY, 2018-2028 ($MILLION)
TABLE 29.    U.S. BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS, 2018-2028 ($MILLION)
TABLE 30.    U.S. BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE, 2018-2028 ($MILLION)
TABLE 31.    U.S. BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2028 ($MILLION)
TABLE 32.    CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS, 2018-2028 ($MILLION)
TABLE 33.    CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE, 2018-2028 ($MILLION)
TABLE 34.    CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2028 ($MILLION)
TABLE 35.    MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS, 2018-2028 ($MILLION)
TABLE 36.    MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE, 2018-2028 ($MILLION)
TABLE 37.    MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2028 ($MILLION)
TABLE 38.    NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS, 2018-2028 ($MILLION)
TABLE 39.    NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE, 2018-2028 ($MILLION)
TABLE 40.    NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2028 ($MILLION)
TABLE 41.    EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY COUNTRY, 2018-2028 ($MILLION)
TABLE 42.    GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS, 2018-2028 ($MILLION)
TABLE 43.    GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE, 2018-2028 ($MILLION)
TABLE 44.    GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2028 ($MILLION)
TABLE 45.    FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS, 2018-2028 ($MILLION)
TABLE 46.    FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE, 2018-2028 ($MILLION)
TABLE 47.    FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2028 ($MILLION)
TABLE 48.    SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS, 2018-2028 ($MILLION)
TABLE 49.    SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE, 2018-2028 ($MILLION)
TABLE 50.    SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2028 ($MILLION)
TABLE 51.    ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS, 2018-2028 ($MILLION)
TABLE 52.    ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE, 2018-2028 ($MILLION)
TABLE 53.    ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2028 ($MILLION)
TABLE 54.    UK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS, 2018-2028 ($MILLION)
TABLE 55.    UK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE, 2018-2028 ($MILLION)
TABLE 56.    UK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2028 ($MILLION)
TABLE 57.    REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS, 2018-2028 ($MILLION)
TABLE 58.    REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE, 2018-2028 ($MILLION)
TABLE 59.    REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2028 ($MILLION)
TABLE 60.    EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS, 2018-2028 ($MILLION)
TABLE 61.    EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE, 2018-2028 ($MILLION)
TABLE 62.    EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2028 ($MILLION)
TABLE 63.    ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY COUNTRY, 2018-2028 ($MILLION)
TABLE 64.    JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS, 2018-2028 ($MILLION)
TABLE 65.    JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE, 2018-2028 ($MILLION)
TABLE 66.    JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2028 ($MILLION)
TABLE 67.    INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS, 2018-2028 ($MILLION)
TABLE 68.    INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE, 2018-2028 ($MILLION)
TABLE 69.    INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2028 ($MILLION)
TABLE 70.    CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS, 2018-2028 ($MILLION)
TABLE 71.    CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE, 2018-2028 ($MILLION)
TABLE 72.    CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2028 ($MILLION)
TABLE 73.    SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS, 2018-2028 ($MILLION)
TABLE 74.    SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE, 2018-2028 ($MILLION)
TABLE 75.    SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2028 ($MILLION)
TABLE 76.    INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS, 2018-2028 ($MILLION)
TABLE 77.    INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE, 2018-2028 ($MILLION)
TABLE 78.    INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2028 ($MILLION)
TABLE 79.    THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS, 2018-2028 ($MILLION)
TABLE 80.    THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE, 2018-2028 ($MILLION)
TABLE 81.    THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2028 ($MILLION)
TABLE 82.    VIETNAM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS, 2018-2028 ($MILLION)
TABLE 83.    VIETNAM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE, 2018-2028 ($MILLION)
TABLE 84.    VIETNAM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2028 ($MILLION)
TABLE 85.    TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS, 2018-2028 ($MILLION)
TABLE 86.    TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE, 2018-2028 ($MILLION)
TABLE 87.    TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2028 ($MILLION)
TABLE 88.    REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS, 2018-2028 ($MILLION)
TABLE 89.    REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE, 2018-2028 ($MILLION)
TABLE 90.    REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2028 ($MILLION)
TABLE 91.    ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS, 2018-2028 ($MILLION)
TABLE 92.    ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE, 2018-2028 ($MILLION)
TABLE 93.    ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2028 ($MILLION)
TABLE 94.    LAMEA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY COUNTRY, 2018-2028 ($MILLION)
TABLE 95.    BRAZIL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS, 2018-2028 ($MILLION)
TABLE 96.    BRAZIL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE, 2018-2028 ($MILLION)
TABLE 97.    BRAZIL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2028 ($MILLION)
TABLE 98.    SAUDI ARABIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS, 2018-2028 ($MILLION)
TABLE 99.    SAUDI ARABIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE, 2018-2028 ($MILLION)
TABLE 100.    SAUDI ARABIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2028 ($MILLION)
TABLE 101.    SOUTH AFRICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS, 2018-2028 ($MILLION)
TABLE 102.    SOUTH AFRICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE, 2018-2028 ($MILLION)
TABLE 103.    SOUTH AFRICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2028 ($MILLION)
TABLE 104.    REST OF LAMEA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS, 2018-2028 ($MILLION)
TABLE 105.    REST OF LAMEA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE, 2018-2028 ($MILLION)
TABLE 106.    REST OF LAMEA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2028 ($MILLION)
TABLE 107.    LAMEA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS, 2018-2028 ($MILLION)
TABLE 108.    LAMEA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE, 2018-2028 ($MILLION)
TABLE 109.    LAMEA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2028 ($MILLION)
TABLE 110.    ABBOTT: COMPANY SNAPSHOT
TABLE 111.    ABBOTT: OPERATING SEGMENTS
TABLE 112.    ABBOTT: PRODUCT PORTFOLIO
TABLE 113.    ALLERGAN: COMPANY SNAPSHOT
TABLE 114.    ALLERGAN: OPERATING SEGMENTS
TABLE 115.    ALLERGAN: PRODUCT PORTFOLIO
TABLE 116.    ROCHE: COMPANY SNAPSHOT
TABLE 117.    ROCHE: OPERATING SEGMENTS
TABLE 118.    ROCHE: PRODUCT PORTFOLIO
TABLE 119.    GSK: COMPANY SNAPSHOT
TABLE 120.    GSK: OPERATING SEGMENTS
TABLE 121.    GSK: PRODUCT PORTFOLIO
TABLE 122.    MERCK: COMPANY SNAPSHOT
TABLE 123.    MERCK: OPERATING SEGMENTS
TABLE 124.    MERCK: PRODUCT PORTFOLIO
TABLE 125.    MYLAN: COMPANY SNAPSHOT
TABLE 126.    MYLAN: OPERATING SEGMENTS
TABLE 127.    MYLAN: PRODUCT PORTFOLIO
TABLE 128.    NOVARTIS AG: COMPANY SNAPSHOT
TABLE 129.    NOVARTIS: OPERATING SEGMENTS
TABLE 130.    NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 131.    PFIZER: COMPANY SNAPSHOT
TABLE 132.    PFIZER: OPERATING SEGMENTS
TABLE 133.    PFIZER: PRODUCT PORTFOLIO
TABLE 134.    SANOFI: COMPANY SNAPSHOT
TABLE 135.    SANOFI: OPERATING SEGMENTS
TABLE 136.    SANOFI: PRODUCT PORTFOLIO
TABLE 137.    TEVA: COMPANY SNAPSHOT
TABLE 138.    TEVA: OPERATING SEGMENTS
TABLE 139.    TEVA: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.    BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET SEGMENTATION
FIGURE 02.    TOP INVESTMENT POCKETS IN THE GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET
FIGURE 03.    TOP WINNING STRATEGIES, BY YEAR, 2015-2019*
FIGURE 04.    TOP WINNING STRATEGIES, BY DEVELOPMENT, 2015-2019* (%)
FIGURE 05.    TOP WINNING STRATEGIES, BY COMPANY, 2015-2019*
FIGURE 06.    GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS TOP PLAYER POSITIONING, 2018
FIGURE 07.    MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.    HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 09.    LOW THREAT OF NEW ENTRANTS
FIGURE 10.    MODERATE THREAT OF SUBSTITUTION
FIGURE 11.    HIGH COMPETITIVE RIVALRY
FIGURE 12.    COMPARATIVE ANALYSIS OF BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR PENICILLIN, BY COUNTRY, 2018 & 2028 ($MILLION)
FIGURE 13.    COMPARATIVE ANALYSIS OF BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR CEPHALOSPORIN, BY COUNTRY, 2018 & 2028 ($MILLION)
FIGURE 14.    COMPARATIVE ANALYSIS OF BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR CARBAPENEM, BY COUNTRY, 2018 & 2028 ($MILLION)
FIGURE 15.    COMPARATIVE ANALYSIS OF BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR MONOBACTAM, BY COUNTRY, 2018 & 2028 ($MILLION)
FIGURE 16.    COMBINATION BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR PENICILLIN/BETA LACTAMASE INHIBITORS, 2018–2028 ($MILLION)
FIGURE 17.    COMBINATION BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR CEPHALOSPORINS/BETA LACTAMASE INHIBITORS, 2018–2028 ($MILLION)
FIGURE 18.    COMBINATION BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET FOR CARBAPENEMS/BETA LACTAMASE INHIBITORS, 2018–2028 ($MILLION)
FIGURE 19.    COMPARATIVE ANALYSIS OF BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR COMBINATION, BY COUNTRY, 2018 & 2028 ($MILLION)
FIGURE 20.    COMPARATIVE ANALYSIS OF BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR URINARY TRACT INFECTION (EXCLUDING CUTI), BY COUNTRY, 2018 & 2028 ($MILLION)
FIGURE 21.    COMPARATIVE ANALYSIS OF BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR RESPIRATORY INFECTION, BY COUNTRY, 2018 & 2028 ($MILLION)
FIGURE 22.    COMPARATIVE ANALYSIS OF BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR SKIN INFECTION, BY COUNTRY, 2018 & 2028 ($MILLION)
FIGURE 23.    COMPARATIVE ANALYSIS OF BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR COMPLICATED URINARY TRACT INFECTION (CUTI), BY COUNTRY, 2018 & 2028 ($MILLION)
FIGURE 24.    COMPARATIVE ANALYSIS OF BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), BY COUNTRY, 2018 & 2028 ($MILLION)
FIGURE 25.    HOSPITAL ACQUIRED PNEUMONIA MARKET, 2018-2028 ($MILLION)
FIGURE 26.    VENTILATOR ASSOCIATED PNEUMONIA MARKET, 2018–2028 ($MILLION)
FIGURE 27.    OTHER NOSOCOMIAL PNEUMONIA MARKET, 2018–2028 ($MILLION)
FIGURE 28.    COMPARATIVE ANALYSIS OF BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR NOSOCOMIAL PNEUMONIA, BY COUNTRY, 2018 & 2028 ($MILLION)
FIGURE 29.    COMPARATIVE ANALYSIS OF BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR BLOOD STREAM INFECTION, BY COUNTRY, 2018 & 2028 ($MILLION)
FIGURE 30.    COMPARATIVE ANALYSIS OF BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR OTHER DISEASES, BY COUNTRY, 2018 & 2028 ($MILLION)
FIGURE 31.    COMPARATIVE ANALYSIS OF BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR ORAL, BY COUNTRY, 2018 & 2028 ($MILLION)
FIGURE 32.    COMPARATIVE ANALYSIS OF BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR INTRAVENOUS, BY COUNTRY, 2018 & 2028 ($MILLION)
FIGURE 33.    COMPARATIVE ANALYSIS OF BETA-LACTAM AND BETA LACTAMASE INHIBITORS MARKET FOR OTHERS, BY COUNTRY, 2018 & 2028 ($MILLION)
FIGURE 34.    ABBOTT: NET SALES, 2016–2018 ($MILLION)
FIGURE 35.    ABBOTT: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 36.    ABBOTT: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 37.    ALLERGAN: NET SALES, 2016–2018 ($MILLION)
FIGURE 38.    ALLERGAN: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 39.    ROCHE: NET SALES, 2016–2018 ($MILLION)
FIGURE 40.    ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 41.    ROCHE: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 42.    GSK: NET SALES, 2016–2018 ($MILLION)
FIGURE 43.    GSK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 44.    GSK: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 45.    MERCK: NET SALES, 2016–2018 ($MILLION)
FIGURE 46.    MERCK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 47.    MERCK: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 48.    MYLAN: NET SALES, 2016–2018 ($MILLION)
FIGURE 49.    MYLAN: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 50.    NOVARTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 51.    NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 52.    NOVARTIS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 53.    PFIZER: NET SALES, 2016–2018 ($MILLION)
FIGURE 54.    PFIZER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 55.    PFIZER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 56.    SANOFI: NET SALES, 2016–2018 ($MILLION)
FIGURE 57.    SANOFI: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 58.    SANOFI: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 59.    TEVA: NET SALES, 2016–2018 ($MILLION)
FIGURE 60.    TEVA: REVENUE SHARE BY REGION, 2018 (%)

 
 

The growth of the beta-lactam and beta-lactamase inhibitors market is expected to increase due to substantial investments in R&D activities by several biotech companies and favorable government legislations. In addition, increased consumption in low and middle-income countries (LMICs), rise in prevalence of infectious diseases, and development of novel approaches for new beta-lactam and beta-lactamase inhibitors for treating bacterial infections and a large number of clinical trials are projected to further drive the market growth during the forecast period. However, development of antibiotic resistance, driven by misuse of beta-lactam and beta-lactamase inhibitors and the increase in drug approval costs are expected to hinder the market growth. 

Asia-Pacific is expected to remain dominant during the forecast period due to increase in consumption of beta-lactam and beta-lactamase inhibitors, cost of antibiotic is less, and high prevalence of bacterial infections in the developing countries. In addition, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to the key players during the forecast period due to rise in antimicrobial resistance, which lead the pharmaceutical companies toward R&D of next generation beta-lactam and beta-lactamase inhibitors.
 

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, Subcription @ $649 T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry

Download Sample

Request Customization

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

FREQUENTLY ASKED
QUESTIONS?

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Beta-lactam and Beta-lactamase Inhibitors Market

  • Online Only
  • $3,456  $3,041
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840  $3,379
  • Restricted to one authorized user
  • One print only
  • Available in Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,370  $4,296
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450  $4,838
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995  $6,297
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Access
  • $0.00
  • Published Content E-Access
  • Company Profiles E-Access
  • Newly Added Content Access
  • 10 PDF Downloads
  • 5 Excel Data Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly
    ,This title and over 12000 thousand more,available with Avenue Library, Subcription @ $649 T&C*

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 
Download Sample